Immunic Therapeutics

Name: Immunic Therapeutics
Address: 1200 Avenue of the Americas, Suite 200, New York, NY, NY10036, US
Telephone: +4989208047700

Home
United States
New York, NY
Immunic Therapeutics

Immunic (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases.

09/18/2026

✨ Marking Chitrang Davé’s appointment as the new Chief Data and Digital Officer of , showcased on the tower in New York City. 🏙️

We look forward to our next phase of growth. Thank you, Nasdaq, for the continued support and welcome again to , Chitrang.

09/17/2026

🧠 While ( ) can affect anyone, women are disproportionately impacted by this neurological disease.

🎗️ This , we recognize how important it is to raise awareness of this disparity because equitable science can mean better care for everyone living with MS.

09/10/2026

✨ Thank you to everyone who joined 's Virtual Relapsing MS R&D Day yesterday.

The discussion highlighted how our understanding of relapsing ( ) continues to evolve, including growing recognition of the ongoing disability progression underlying the disease, persistent unmet needs for patients, and emerging scientific approaches that may help address them.

🤝 We are particularly grateful to Dr. Amit Bar-Or and Dr. Stephen Krieger for sharing their expertise at our event and helping advance an important scientific dialogue.

Missed the event? Watch the replay here: https://bit.ly/4xcZ4ep

09/08/2026

🧠 What can attendees expect from 's Relapsing MS R&D Day tomorrow?

Together with leading ( ) experts, we will discuss advances in relapsing multiple sclerosis ( ) biology, persistent unmet needs, and the scientific rationale behind calcium, our late-stage clinical development program.

We will also explore the evolving treatment landscape and future opportunities in RMS research as we approach our anticipated phase 3 top-line data readout, expected by the end of 2026.

👉 Register here: https://bit.ly/4i843t0

09/07/2026

🧠 Why do some persons with relapsing multiple sclerosis ( ) continue to experience disease progression, even when relapses are under control?

This question is at the center of ongoing research and will also be discussed during 's RMS R&D Day on September 9, featuring leading ( ) experts Dr. Amit Bar-Or and Dr. Stephen Krieger and our manangement team.

Join us as they discuss emerging insights around the MS patient journey, current treatment paradigms, and unmet medical needs.

👉 Learn more and register: https://bit.ly/4zQc5gp

09/03/2026

During , we are celebrating the women at whose curiosity, dedication, and commitment to improving patients' lives help move ( ) research forward.

From the lab to the clinic, their work helps us better understand chronic inflammatory and autoimmune diseases like MS and brings us closer to new treatment options for the people living with them.

💪 We are proud to support the women pioneering science and medicine and driving the development of novel therapies.

09/02/2026

✨ As we move closer to the anticipated top-line phase 3 data readout, expected by the end of 2026, we remain focused on advancing our potential new treatment option for people living with relapsing ( , ).

🧠 Ahead of this important milestone, we will host a virtual RMS R&D Day on September 9, 2026, providing an opportunity to discuss the science behind calcium, our late-stage clinical development program, and persistent unmet needs in relapsing .

Members of 's management team will be joined by two internationally renowned MS experts for the event. Don't miss it!

👉 Read more: https://bit.ly/4zQc5gp

09/01/2026

✨ As advances toward key milestones for its ( ) development program, we are continuing to strengthen our .

We are pleased to welcome Chitrang Davé as 's new Chief Data and Digital Officer.

📊 In this newly created role, Chitrang will lead the company's enterprise-wide data systems, , and digital strategy, building a unified, commercial-ready ecosystem that supports our transition from late-stage clinical development toward potential regulatory submissions and commercialization.

👏 We look forward to the expertise and leadership Chitrang brings to the team at this important stage of our development.

Read more: https://bit.ly/4i4zPH7

08/31/2026

☀️ Summer may be winding down, but the journey continues.

From new scientific publications and conference presentations to leadership appointments, industry recognition and continued progress in our clinical development, it has been a busy and productive summer at . 🔬

As we look back on a few highlights from the past months, we are grateful to our employees, collaborators, investigators and members of the broader ( ) and scientific communities who continue to support and shape our journey.

🍂 We are looking forward to what the remainder of 2026 has in store.

Address

1200 Avenue Of The Americas, Suite 200
New York, NY
NY10036

Telephone

+4989208047700

Website

https://www.imux.com/

Alerts

Be the first to know and let us send you an email when Immunic Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Business in New York?